D. Tang

发表

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective

Anand A. Dalal, D. Brixner, J. Biskupiak, 2018, Journal of managed care & specialty pharmacy.

Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer

Jipan Xie, E. Wu, R. Ayyagari, 2017, Advances in Therapy.

Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis

Anand A. Dalal, D. Chandiwana, Jipan Xie, 2018, Current medical research and opinion.

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer

A. Bardia, A. Aizer, N. Princic, 2018, Current medical research and opinion.

Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients

D. Cella, D. Revicki, D. Tang, 2019, Health and Quality of Life Outcomes.

Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings

D. Cella, D. Revicki, D. Tang, 2019, Journal of Patient-Reported Outcomes.

Abstract 1207: A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2- metastatic breast cancer

T. Warholak, A. Aizer, L. Davis, 2018, Epidemiology.

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.

T. Warholak, A. Aizer, L. Davis, 2019, Clinical breast cancer.

Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States

I. Pivneva, K. Seiter, G. Joseph, 2018, Advances in Therapy.

Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.

N. Vogelzang, E. Swallow, S. Ravichandran, 2019, Clinical genitourinary cancer.

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

T. Warholak, A. Aizer, L. Davis, 2020, International journal of breast cancer.

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study

Y. Hao, E. Wu, A. Fang, 2016, Expert opinion on pharmacotherapy.

Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic breast cancer

Anand A. Dalal, D. Brixner, R. Hettle, 2018, Current medical research and opinion.

First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study

Jipan Xie, N. Li, E. Du, 2017, Current medical research and opinion.

Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.

Anand A. Dalal, D. Brixner, J. Biskupiak, 2019, Journal of managed care & specialty pharmacy.

Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer

Jipan Xie, E. Du, D. Tang, 2017, Expert opinion on pharmacotherapy.

Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.

Anand A. Dalal, D. Chandiwana, Jipan Xie, 2018, Clinical therapeutics.